WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318597

CAS#: 36735-22-5

Description: Quazepam is indicated for the treatment of insomnia including sleep induction and sleep maintenance. Quazepam induces impairment of motor function and has hypnotic and anticonvulsant properties with less overdose potential than other benzodiazepines. Quazepam is an effective hypnotic which induces and maintains sleep without disruption of the sleep architecture. Quazepam is unique amongst benzodiazepines in that it selectively targets the GABAA α1 subunit receptors which are responsible for inducing sleep. Its mechanism of action is very similar to zolpidem and zaleplon in its pharmacology and can successfully substitute for zolpidem and zaleplon in animal studies.

Price and Availability


USD 600


Quazepamhttps, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 318597
Name: Quazepam
CAS#: 36735-22-5
Chemical Formula: C17H11ClF4N2S
Exact Mass: 386.02676
Molecular Weight: 386.79
Elemental Analysis: C, 52.79; H, 2.87; Cl, 9.17; F, 19.65; N, 7.24; S, 8.29

Synonym: Quazepam; Dormalin; Prosedar; Oniria; Quazium; Selepam; quazepam; Quiedorm; Sch 16134;

IUPAC/Chemical Name: 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione


InChi Code: InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2

SMILES Code: C1C(=S)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CC(F)(F)F

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Yamaguchi K, Goda T, Yamaki S, Ohno Y. Structural analysis of quazepam
metabolites in bile by ion trap time-of-flight mass spectrometry. Forensic Sci
Int. 2015 Nov;256:7-16. doi: 10.1016/j.forsciint.2015.07.016. Epub 2015 Jul 17.
PubMed PMID: 26301753.

2: Zhou J, Yamaguchi K, Ohno Y. Quantitative analysis of quazepam and its
metabolites in human blood, urine, and bile by liquid chromatography-tandem mass
spectrometry. Forensic Sci Int. 2014 Aug;241:e5-12. doi:
10.1016/j.forsciint.2014.04.027. Epub 2014 May 5. PubMed PMID: 24856286.

3: Terada M, Shinozuka T, Hasegawa C, Tanaka E, Hayashida M, Ohno Y, Kurosaki K.
Analysis of quazepam and its metabolites in human urine by gas
chromatography-mass spectrometry: application to a forensic case. Forensic Sci
Int. 2013 Apr 10;227(1-3):95-9. doi: 10.1016/j.forsciint.2012.11.017. Epub 2013
Jan 3. PubMed PMID: 23290298.

4: Nishiyama T, Yamashita K, Yokoyama T, Imoto A, Manabe M. Effects of quazepam
as a preoperative night hypnotic: comparison with brotizolam. J Anesth.
2007;21(1):7-12. Epub 2007 Jan 30. PubMed PMID: 17285406.

5: Sugimoto K, Araki N, Ohmori M, Harada K, Cui Y, Tsuruoka S, Kawaguchi A,
Fujimura A. Interaction between grapefruit juice and hypnotic drugs: comparison
of triazolam and quazepam. Eur J Clin Pharmacol. 2006 Mar;62(3):209-15. Epub 2006
Jan 17. PubMed PMID: 16416305.

6: Kanda H, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Otani K.
Interaction study between fluvoxamine and quazepam. J Clin Pharmacol. 2003
Dec;43(12):1392-7. PubMed PMID: 14615476.

7: Roth TG, Roehrs TA, Koshorek GL, Greenblatt DJ, Rosenthal LD. Hypnotic effects
of low doses of quazepam in older insomniacs. J Clin Psychopharmacol. 1997
Oct;17(5):401-6. PubMed PMID: 9315991.

8: Mendels J. Evaluation of the safety and efficacy of quazepam for the treatment
of insomnia in psychiatric outpatients. J Clin Psychiatry. 1994 Feb;55(2):60-5.
PubMed PMID: 7915708.

9: Saletu B, Anderer P, Brandstätter N, Frey R, Grünberger J, Klösch G, Mandl M,
Wetter T, Zeitlhofer J. Insomnia in generalized anxiety disorder:
polysomnographic, psychometric and clinical investigations before, during and
after therapy with a long- versus a short-half-life benzodiazepine (quazepam
versus triazolam). Neuropsychobiology. 1994;29(2):69-90. PubMed PMID: 8170529.

10: Scharf MB. Feasibility of an every-other-night regimen in insomniac patients:
subjective hypnotic effectiveness of quazepam, triazolam, and placebo. J Clin
Psychiatry. 1993 Jan;54(1):33-8. PubMed PMID: 8428895.

11: Mauri MC, Gianetti S, Pugnetti L, Altamura AC. Quazepam versus triazolam in
patients with sleep disorders: a double-blind study. Int J Clin Pharmacol Res.
1993;13(3):173-7. PubMed PMID: 7901174.

12: Hilbert JM, Battista D. Quazepam and flurazepam: differential pharmacokinetic
and pharmacodynamic characteristics. J Clin Psychiatry. 1991 Sep;52 Suppl:21-6.
Review. PubMed PMID: 1680120.

13: Quazepam: a new hypnotic. Med Lett Drugs Ther. 1990 Apr 20;32(816):39-40.
PubMed PMID: 1970112.

14: Blom MW, Bartel PR, de Sommers K, Van der Meyden CH, Becker PJ. The effects
of alprazolam, quazepam and diazepam on saccadic eye movements, parameters of
psychomotor function and the EEG. Fundam Clin Pharmacol. 1990;4(6):653-61. PubMed
PMID: 1982881.

15: Giorgi O, Corda MG, Gritti I, Mariotti M, Ongini E, Biggio G. Binding sites
for [3H]2-oxo-quazepam in the brain of the cat: evidence for heterogeneity of
benzodiazepine recognition sites. Neuropharmacology. 1989 Jul;28(7):715-8. PubMed
PMID: 2569691.

16: Schölermann K, Kazemian-Erdmann F, Schütz H. [Screening and detection of
quazepam and its metabolites]. Arzneimittelforschung. 1989 May;39(5):556-9.
German. PubMed PMID: 2569308.

17: Schaffler K, Kauert G, Wauschkuhn CH, Klausnitzer W. Longitudinal study on
pharmacodynamics and pharmacokinetics of acute, steady-state and withdrawn
quazepam. Arzneimittelforschung. 1989 Feb;39(2):276-83. PubMed PMID: 2567171.

18: Wettstein JG. Effects of the novel benzodiazepine agonist quazepam on
suppressed behavior of monkeys. Eur J Pharmacol. 1988 Oct 11;155(1-2):19-25.
PubMed PMID: 2907488.

19: Oelschläger H, Volke J, Linde HF, Fedai I, Schmidt W. [Drug analysis with
polarographic methods. XXXII. Reasons for the anomalous current-voltage curves of
quazepam [7-chloro-5-(2-fluoro-phenyl)
-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione]. Arch Pharm
(Weinheim). 1988 Aug;321(8):457-62. German. PubMed PMID: 2906236.

20: Gupta SK, Ellinwood EH Jr. Liquid chromatographic assay and pharmacokinetics
of quazepam and its metabolites following sublingual administration of quazepam.
Pharm Res. 1988 Jun;5(6):365-8. PubMed PMID: 3244647.